ETFs StemRIM

4599

JP3399690001

Pharmaceuticals

Market Closed - Japan Exchange 09:30:00 11/09/2026 +03			5-day change	1st Jan Change
180.00 ^JPY	-24.69%		-42.31%	-31.56%

09-09	StemRIM Reports Earnings Results for the Full Year Ended July 31, 2026	CI
07-22	Stemrim Announces Patent Registration in Mexico for Redasemtide as Therapeutic Agent for Cartilage Disorders	CI

ETFs positioned on StemRIM

Name		YTD change	Weight	AuM
ISHARES INTERNATIONAL SMALL-CAP EQUITY FACTOR ETF - USD		+9.43%	0.01%	679 M€

StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Companyâ€™s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.

Employees

Sector

Pharmaceuticals

More about the company